Temporal trends in the characteristics of children at antiretroviral therapy initiation in southern Africa: the IeDEA-SA Collaboration by Davies, Mary-Ann et al.
Temporal Trends in the Characteristics of Children at
Antiretroviral Therapy Initiation in Southern Africa: The
IeDEA-SA Collaboration
Mary-Ann Davies1*, Sam Phiri2, Robin Wood3, Maureen Wellington4, Vivian Cox5, Carolyn Bolton-
Moore6, Venessa Timmerman7, Harry Moultrie8, James Ndirangu9, Helena Rabie10, Karl Technau11,
Janet Giddy12, Nicola Maxwell1, Andrew Boulle1, Olivia Keiser13, Matthias Egger13, Brian Eley14, IeDEA
Southern Africa Steering Group"
1 School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa, 2 Lighthouse Trust Clinic, Kamuzu Central Hospital, Lilongwe, Malawi,
3Gugulethu Community Health Centre and Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town,
South Africa, 4Newlands Clinic, Harare, Zimbabwe, 5Me´decins Sans Frontie`res South Africa and Khayelitsha ART Programme, Khayelitsha, Cape Town, South Africa,
6Centre for Infectious Disease Research in Zambia, Lusaka, Zambia and University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America,
7 Knowledge Translation Unit, University of Cape Town Lung Institute, Cape Town, South Africa, 8Wits Reproductive Health and HIV Institute, Harriet Shezi Children’s
Clinic, Chris Hani Baragwanath Hospital, Faculty of Health Sciences, University of Witwatersrand, Soweto, Johannesburg, South Africa, 9Africa Centre for Health and
Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, 10 Tygerberg Academic Hospital, University of Stellenbosch, Stellenbosch, South Africa,
11 Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital and University of Witwatersrand, Johannesburg, South Africa, 12 Sinikithemba Clinic,
McCord Hospital, Durban, South Africa, 13 Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland, 14 Red Cross Children’s Hospital and
School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
Abstract
Background: Since 2005, increasing numbers of children have started antiretroviral therapy (ART) in sub-Saharan Africa and,
in recent years, WHO and country treatment guidelines have recommended ART initiation for all infants and very young
children, and at higher CD4 thresholds for older children. We examined temporal changes in patient and regimen
characteristics at ART start using data from 12 cohorts in 4 countries participating in the IeDEA-SA collaboration.
Methodology/Principal Findings: Data from 30,300 ART-naı¨ve children aged ,16 years at ART initiation who started
therapy between 2005 and 2010 were analysed. We examined changes in median values for continuous variables using the
Cuzick’s test for trend over time. We also examined changes in the proportions of patients with particular disease severity
characteristics (expressed as a binary variable e.g. WHO Stage III/IV vs I/II) using logistic regression. Between 2005 and 2010
the number of children starting ART each year increased and median age declined from 63 months (2006) to 56 months
(2010). Both the proportion of children ,1 year and $10 years of age increased from 12 to 19% and 18 to 22% respectively.
Children had less severe disease at ART initiation in later years with significant declines in the percentage with severe
immunosuppression (81 to 63%), WHO Stage III/IV disease (75 to 62%), severe anemia (12 to 7%) and weight-for-age z-
score,23 (31 to 28%). Similar results were seen when restricting to infants with significant declines in the proportion with
severe immunodeficiency (98 to 82%) and Stage III/IV disease (81 to 63%). First-line regimen use followed country
guidelines.
Conclusions/Significance: Between 2005 and 2010 increasing numbers of children have initiated ART with a decline in
disease severity at start of therapy. However, even in 2010, a substantial number of infants and children started ART with
advanced disease. These results highlight the importance of efforts to improve access to HIV diagnostic testing and ART in
children.
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Introduction
The estimated number of children receiving antiretroviral
therapy (ART) in southern and eastern Africa has increased
several-fold from ,50,000 in 2005 to 337,200 by the end of
December 2010, corresponding to a coverage of 26% of those
eligible for ART [1]. In addition, WHO 2010 guidelines
recommended immediate ART for HIV infected children ,2
years of age irrespective of disease severity, and ART at much
higher CD4 thresholds than before in older children [2]. This
means that more children are starting therapy and increasingly
those initiating treatment should have less advanced disease.
Furthermore, although drug development, availability and acces-
sibility for children lags behind that of adults [3,4], there have
been moves towards less toxic and more effective first-line ART
[2].
Timely ART initiation is important especially in infants and
young children where disease progression is rapid and mortality is
high [5,6]. Even after ART initiation, early mortality remains very
high in children with advanced disease, whereas starting ART
with less advanced disease is associated with a good prognosis in
terms of mortality, immunological, growth and neurodevelop-
mental outcomes [7,8,9,10,11,12]. There have been few articles
published examining temporal trends in children initiating ART in
sub-Saharan Africa [13,14,15,16]. During the early years of
pediatric ART availability in South Africa between 2003 and
2007, ART initiation at 7 pediatric sites increased threefold and
median baseline CD4% among children,5 years of age increased
[17]. A subsequent South African study (2005–2009) found that in
later years children had less severe disease and there were
increasing proportions both of very young (,18 months) and older
($10 years) children initiating therapy [13]. Comparison of
secular trends in a study of 565 children initiating ART at urban
and rural clinics in Zambia showed trends towards decreasing age
and increasing CD4% with later years, however the study was
small and changes were not all significant [14].
The International epidemiologic Databases to Evaluate AIDS
Southern Africa (IeDEA-SA) collaboration now includes individ-
ualized data on .35,000 children ever started on ART across 12
sites in southern Africa. This provides an opportunity to examine
temporal trends in baseline characteristics and regimen use in a
very large cohort across a range of settings in 4 countries (Malawi,
South Africa, Zambia and Zimbabwe). This is important to
determine the extent to which HIV care and treatment
programmes have expanded and timely ART initiation has
improved in recent years, especially in relation to WHO and
country guideline changes. It is also useful for planning programs.
In addition to examining characteristics across the cohort as a
whole, we particularly aimed to focus on changes in infants
starting therapy as the Children with HIV Early Antiretroviral
Therapy (CHER) trial has shown that ART initiation in infants
before disease progression substantially reduces mortality and
morbidity [2,12,18,19].
Methods
The IeDEA Southern Africa Collaboration has been approved
by the University of Cape Town and University of Bern human
research ethics committees. The requirement for informed consent
has been waived as only anonymized data that is already collected
as part of routine monitoring is contributed to the collaborative
dataset. All sites have local institutional ethics approval to
contribute data to IeDEA-SA analyses as follows: University of
Zambia Biomedical Research Ethics Committee (Zambian Min-
istry of Health [MOH] – Centre for Infectious Disease Research
in Zambia [CIDRZ]); University of Cape Town (Free State
Province, Gugulethu Community Health Centre, Khayelitsha
ART Programme, McCord Hospital, Red Cross Children’s
Hospital); University of KwaZulu Natal (Hlabisa HIV Care and
Treatment Programme); University of Witwatersrand (Harriet
Shezi Clinic, Rahima Moosa Mother and Child Hospital); Malawi
National Health Sciences Research Ethics Committee (Lighthouse
Clinic); Medical Research Council of Zimbabwe (Newlands Clinic)
and University of Stellenbosch (Tygerberg Academic Hospital).
The IeDEA-SA collaboration has been described previously and
currently includes 12 HIV care and treatment programs for
children in 4 southern African countries (www.iedea-sa.org) [9,20].
Longitudinal data are collected prospectively at each site at ART
initiation (baseline) and follow-up visits, using standardized
definitions. Anonymized data are transferred to data centers at
the Universities of Cape Town, South Africa, or Bern,
Switzerland, in a standardized format and merged at regular
intervals. We included all ART-naı¨ve children (except for
exposure to antiretrovirals to prevent mother to child transmission
[PMTCT]) starting therapy at age ,16 years between 1 January
2005 and 31 December 2010. Children starting before 2005 were
excluded to limit the analysis to children likely to have presented
after ART roll-out began. Children starting after 2010 were
excluded as most cohorts transferred data during 2011 and so full
data for that year is not available. The Hlabisa (South Africa) and
Newlands (Zimbabwe) cohorts transferred data during 2010, and
so did not contribute a full year of data for 2010. Children with a
documented HIV-RNA measurement ,400 copies/ml at baseline
were excluded as they were unlikely to be ART-naı¨ve.
Laboratory and anthropometric disease severity characteristics
at ART start were the characteristics measured at the date closest
to ART initiation within a window of 26 months to +7 days for
CD4%/count, HIV-RNA and hemoglobin and a window of 21
month to +2 weeks for weight, height and body mass index (BMI).
Weight-for-age, height-for-age and BMI-for-age z-scores (WAZ,
HAZ, BAZ) were calculated using WHO 2006 standards [21].
BAZ was used rather than weight-for-height z-scores as these can
be calculated for all ages, whereas weight-for-height standards are
only available for children ,5 years of age. Severe immune
suppression was defined using the worst of CD4% and count, or
whichever measure was available, using age-specific thresholds
according to WHO guidelines [22]. Severe anemia was defined
according to both hemoglobin and age using Division of AIDS
criteria for grading of adverse events [23].
We examined changes over the duration of the program in
continuous variables (using medians and interquartile ranges
[IQR]) and in categorical variables (using proportions) for all
children, and separately for those ,1 year old at ART start.
Changes in median values were assessed using the Cuzick’s test for
trend over the ordered groups of program year. Changes in the
proportion of patients with a particular disease severity charac-
teristic (expressed as a binary variable e.g. WHO Stage III/IV vs
I/II) over the duration of the program were tested using
unadjusted logistic regression with the disease severity character-
istic as the dependent variable and examining the linear trend over
program years as the independent variable. All analyses were done
using STATA 12.0 (College Station, Texas, USA).
Results
Characteristics of all children starting therapy
Between 2005 and 2010, 30,300 ART-naı¨ve children initiated
ART at 12 IeDEA-SA treatment programs in 4 countries and
were included in the analysis. There was considerable heteroge-
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neity in program characteristics and the number (median
1,178; range across sites: 402–12,378), and characteristics of
children initiating treatment at each program (Table 1;
Figure 1; Supplementary Table S1 in File S1). Programs
ranged from single hospital facilities providing pediatric tertiary
care to a number of clinics and hospitals providing all levels of
care for adults and children across a health district or province.
Median (IQR) age at ART initiation was 58 (20–109) months;
range across sites 8–113. As expected with such heterogeneity
in age, there was variability in CD4 count with median (IQR)
of 381 (180–734) cells/mm3; range across sites: 193–647.
CD4% was less variable with median (IQR) of 14.0% (8.9–
20.0); range across sites: 12.0–17.0. Overall, 70% of children
were severely immunosuppressed and 72% had WHO Stage
III/IV disease with ranges across sites of 54–84% and 28–93%
respectively. Median (IQR) WAZ was 22.01 (23.23 to 20.97)
and 29% of children ,10 years old had WAZ,23 (range
across sites 13–40%). Variables were frequently not available
for all children. Overall the proportions of missing data for
WHO Stage, CD4%/count, haemoglobin and weight were
19%, 34%, 47% and 22%. The median (IQR) number of days
between variable measurement and ART start date was 221
(244 to 29) (CD4 count), 223 (246 to 212) (CD4%), 220
(245 to 0) (HIV-RNA) 216 (234 to 26) (hemoglobin) and 0 (0
to 0) for WAZ.
Table 1. Characteristics of cohorts.
Cohort name and
location
Main level of care
provided Multiple facilities
Type of clinic and
payment Target population
Number of
children ever
started on ART
since program
start
Number of children
included in the
analysis (started
ART between 1 Jan
2005 and 31 Dec
2010)
Zambian MOH-
CIDRZ, Lusaka,
Zambia
Primary Yes Public, Free ART Adults and children,
combined clinics
14,500 12,378
Free State Province,
South Africa
All levels Yes Public and research,
Free ART
Adults and children,
combined clinics
4,629 4,579
Gugulethu
Community Health
Centre, Cape Town,
South Africa
Primary No Public and research,
Free ART
Adults and children,
separate clinics
483 402
Hlabisa HIV Care
and Treatment
Programme,
Kwazulu-Natal,
South Africa
Primary Yes Public, Free ART Adults and children,
combined clinics
1141 1134
Harriet Shezi, Chris
Hani Baragwanath
Hospital, Soweto,
South Africa
All levels No Public and research,
Free ART
Children only 4,629 3,996
Khayelitsha
Community Health
Centre, Cape Town,
South Africa
Primary Yes Public, Free ART Adults and children,
separate clinics
1,191 919
Lighthouse Clinic,
Kamuzu Central
Hospital, Lilongwe,
Malawi
All levels No Public, Free ART Adults and children,
separate clinics
1,416 1,221
McCord Hospital,
Durban, South
Africa
Secondary No Private not-for-profit;
Small co-payment
Adults and children,
separate clinics
804 735
Newlands Clinic,
Harare, Zimbabwe
Secondary No Public, Free ART Adults and children,
separate clinics
874 829
Red Cross Children’s
Hospital, Cape
Town, South Africa
Tertiary No Public and research;
Free ART
Children only 1,873 1,360
Rahima Moosa
Mother and Child
Hospital,
Johannesburg,
South Africa
All levels No Public, Free ART Children and
pregnant women
2,198 1,854
Tygerberg Hospital,
Cape Town, South
Africa
Tertiary No Public and research,
Free ART
Adults and children,
separate clinics
1,307 893
TOTAL 35,045 30,300
doi:10.1371/journal.pone.0081037.t001
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Changes in guidelines and temporal trends in child
characteristics
Most programs followed national guidelines for ART initiation
and first-line regimen choice which were based on WHO
guidelines (Figure 2) [24,25,26,27,28,29]. There were sometimes
lags or minor discrepancies between WHO recommendations and
national guidelines. For example, while the WHO 2010 guidelines
recommend ART initiation for all children ,24 months old
irrespective of disease severity, this was implemented in Zambia in
2011. South Africa implemented ART irrespective of disease
severity for infants ,12 months in April 2010, but this was only
expanded to children 12–24 months of age in 2012, when ART for
all children ,5 year of age irrespective of disease severity was
recommended [30].
The number of children starting therapy increased each year
from 3,849 in 2005 to 6,368 in 2009 (Figure 3). There was a slight
decline in 2010, however 2 programs transferred data before the
year ended. The median age dropped from a peak of 63 months in
2006 to 56 months in 2010 (p,0.001). Both the proportion of
children ,1 year and $10 years increased over time from 12 to
19% (p,0.001) and 18 to 22% (p,0.001) respectively. Children
had less severe disease at ART initiation in later years for almost
all markers – baseline CD4%/count increased and there were
significant declines in the proportions with severe immunosup-
pression (81 to 63%; p,0.001), WHO Stage III/IV disease (75 to
62%; p,0.001) and severe anemia (12 to 7%; p,0.001) (Figure 3;
Supplementary Table S2 in File S1). Nutritional status improved
slightly e.g. the proportion with WAZ,23 decreased from 31 to
28% (p,0.001) and other nutritional indices showed similar
trends. Completeness of data for most variables increased over
time e.g. the proportion with missing data on weight and
hemoglobin dropped from 30 to 18% and 60 to 41%. Notable
exceptions were CD4%/count where the proportion of missing
data was constant and HIV-RNA where it increased from 43% to
61%. Median HIV-RNA and proportion with .5 log10 copies/ml
showed a curious pattern of first decreasing and then increasing in
2010, however there was still a significant trend to lower values in
the later years.
Temporal trends were mostly similar when looking separately at
sites from within and outside South Africa (Supplementary Table
S3 in File S1). The only notable difference was in the proportion of
children in different age groups. The proportion of children ,1
year of age increased in later years across the entire region, but the
proportion in South Africa in 2010 (25.7%) was much higher than
in the rest of the region (12.7%). The proportion of children aged
1–2 years increased in sites from outside South Africa, but not in
Figure 1. Characteristics of children at ART start in the different cohorts. Characteristics of children at ART start in the different cohorts
(median [IQR] age, weight-for-age z-score [WAZ], CD4 count and percent).
doi:10.1371/journal.pone.0081037.g001
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South African sites. The proportion of children $10 years
increased in South Africa but decreased in sites from outside
South Africa.
Temporal trends in characteristics of children ,1 year of
age
The number of children ,1 year old at ART initiation more
than doubled from 475 in 2005 to a peak of 1,114 in 2009, with a
slight drop in 2010 (Figure 4, Supplementary Table S4 in File S1).
Median age at ART start in children ,1 year dropped from 6.9 to
5.6 months. Children ,1 year at ART start in later years had less
severe disease. Median CD4%/count increased (p,0.001) and the
proportion with severe immunodeficiency dropped from 98 to
82% and with WHO Stage III/IV disease from 81 to 63%. In
2005 nearly 60% of infants were severely underweight at ART
start and this declined to 35% in 2010, with similar improvements
in HAZ and BAZ.
First-line regimen
Almost all first-line regimens were an option selected from
nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)1
(stavudine [d4T]/zidovudine [AZT]/abacavir [ABC]/tenofovir
[TDF])+NRTI2 (lamivudine [3TC]/emtricitabine [FTC])+pro-
tease inhibitor (PI)/non-nucleoside reverse transcriptase inhibitor
(NNRTI). First-line regimen differed for sites from within and
outside South Africa and for children younger and older than 3
years. This is in keeping with national guidelines and drug
prescribing information – dosing for efavirenz (EFV) was not
established for children ,3years/10 kg; outside South Africa
nevirapine (NVP) was recommended as the ‘‘third drug’’ for all
children, while South African guidelines recommended PIs for
children ,3 years/10 kg, and EFV in older children. Across all
age groups, 3TC predominated as NRTI2.
NRTI1: Outside South Africa d4T use was predominant and
increased over time from 61% to 81% (p,0.001) and 66% to 71%
(p,0.001) in children below and above 3 years of age, with
corresponding declines in AZT use. There were also small
increases over time in ABC use for all children and TDF for
children .3 years. Within South Africa d4T use increased slightly
in children ,3years from 2005 to 2009 (83 to 89%) with
corresponding declines in AZT, but was constant at 96–97% in
older children. In both age groups a change was seen in 2010 with
proportion starting d4T dropping to 41% and 60% in children
younger and older than 3 years, with ABC replacing d4T as the
NRTI1 of choice. There was negligible use of TDF.
NNRTI/PI: Outside South Africa NVP use was predominant in
both age groups: 97 and 87% of children younger and older than 3
years. Almost all of the remainder of children initiated EFV, use of
which increased over time in older children from 8 to 16%
(p,0.001). There was negligible use of PIs. Inside South Africa in
children ,3 years, NVP use declined from 9% in 2005 to ,1% in
2010 (p,0.001) with corresponding increases in lopinavir-
ritonavir (LPV/r) use. In 2005 and 2006, 11% of children ,3
years initiated therapy with ritonavir alone as the third drug, but
this was almost completely eliminated from 2007 onwards when
LPV/r dosing recommendations for children ,6 months of age
were introduced and double dose LPV/r or ritonavir-boosted
LPV/r were used when co-treating for tuberculosis. EFV
predominated in children .3 years (93% of children) with no
temporal changes.
Discussion
This analysis of .30,000 children who started ART across
Southern Africa between 2005 and 2010 demonstrates that not
only is the number of children starting therapy increasing, but also
that in recent years children are younger and less severely ill at
ART start. Nevertheless, even in 2010 many children were still
initiating therapy with advanced disease 262% with WHO Stage
III/IV disease, 29% with WAZ,23 and 63% were severely
immunosuppressed.
Similar temporal trends in disease severity characteristics were
noted in a South African study of 3,000 children initiating therapy
at 30 health facilities between 2005 to 2009 [13], as well as in
Zambia [14], Both the South African and Zambian studies showed
temporal improvements in mortality [13,14]. Initiating therapy
earlier in the course of disease is important as children with less
severe disease experience better outcomes on ART and, in
particular, the high early mortality seen in children starting
therapy in resource-limited settings may be attenuated
[7,31,32,33,34,35,36]. Early ART also improves neurodevelop-
mental outcomes in infants [12]. As has been found in adult
studies, however, in Zambia there was also increasing loss to
follow-up over time which may include unascertained mortality
Figure 2. WHO and country antiretroviral therapy guidelines for children from 2004–2011.
doi:10.1371/journal.pone.0081037.g002
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[14,37,38]. Encouragingly in the South African study loss to
follow-up did not increase over time [13].
It appears there is a mixed pattern of temporal trends in age
with increasing proportions of infants as well as older children and
adolescents initiating therapy, although the latter was only seen at
South African sites [13]. Despite temporal increases, the propor-
tion of infants initiating therapy in our study was still low especially
in sites outside South Africa, reaching 19% across the region in
2010. Nevertheless this is substantially higher than in previously
published studies and may be due to the inclusion of data from
2010 after most countries had adopted universal ART for children
,1 year, as well as inclusion of 2 sites providing exclusive tertiary
care in South Africa where .50% of children were infants. It is
notable that there was no increase in the proportion of children
aged 1–2 years at ART initiation in South Africa, as this is the only
country in the region where the WHO 2010 recommendation of
ART initiation irrespective of disease severity was restricted to
children ,1 year, rather than ,2 years of age as was adopted in
other countries. The proportion of children starting therapy in
infancy is complex as it is a composite result of the ability of health
care services to promptly diagnose and initiate infants on therapy,
the coverage and effectiveness of PMTCT programs in reducing
numbers of newly infected infants, as well as the backlog of older
children not yet initiated on therapy. Indeed, the curious increase
in median log10 viral load values in 2010 may be due to both the
younger age of infants starting ART and increasing coverage and
effectiveness of PMTCT, with high HIV-RNA values in young
infants infected despite PMTCT exposure [30]. The backlog of
older children not yet on ART may be substantial and is an
important consideration in designing pediatric HIV care and ART
programs as the needs and disease spectrum in these children are
different from infants and toddlers [39,40,41]. In our study 1,151
children $10 years of age (22% of all children) initiated therapy in
2010, however these were not all confirmed to be infected
Figure 3. Characteristics of children at ART start by program year. Characteristics of children at ART start by program year summarized as
medians for continuous variables and proportions for categorical variables. p,0.001 for changes over program year for all variables (Cuzick’s test for
trend for continuous variables and logistic regression for categorical variables). (Note: Only children ,10 years of age included in weight-for-age z-
score graphs and only South African sites included for graphs of HIV-RNA.)
doi:10.1371/journal.pone.0081037.g003
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perinatally, rather than through sexual transmission. Other studies
have found considerable numbers of perinatally infected children
being diagnosed with HIV in late childhood or adolescence
[39,42,43].
Despite temporal improvements across all ages in disease
severity at ART start, the proportion of children initiating therapy
with severe disease even at the end of the analysis period is a
concern. Even in 2010, the median CD4%, WAZ and log10 HIV-
RNA in our study indicated markedly more severe disease than
those from a review of studies from developed countries [8]. This
highlights the need to scale up provider-initiated testing and
counselling for children at all health care encounters such as
vaccination clinics, outpatient and inpatient services in order to
ensure prompt diagnosis of HIV and initiation of therapy in those
that need it [44,45]. In this respect the recently updated WHO
2013 guidelines [46] recommending ART initiation in all children
,5 years of age irrespective of disease severity may reduce barriers
to starting ART and streamline initiation. Delayed ART initiation
is a particular concern for infants where early ART before disease
progression substantially reduces mortality and morbidity [18]. In
our study in 2010, .60% of infants started therapy with WHO
Stage III/IV disease and .80% with severe immune suppression.
The median age of infants starting ART in 2010 was 5.6 months
which is well above the median age of ,2 months in the
immediate arm of the CHER Study. There are a number of
barriers to early ART initiation including lack of access to HIV-
DNA PCR testing for diagnosis [24,47,48,49], poor integration of
antenatal, PMTCT, maternal and child health (MCH) and HIV
services with poor infant HIV testing even among those whose
mothers enrolled in PMTCT care [50], lack of expertise,
experience and confidence with initiating and maintaining infants
on ART and poor availability of drugs in suitable formulations for
infants [4,51]. Strategies to improve ART access for infants such as
integration of PMTCT, MCH and HIV services and provider
initiated testing at vaccination and other health visits [45,52,53,54]
need to be developed and expanded. In Zambia, the median age
of children enrolling in HIV care declined in settings where there
was close collaboration between the MCH service and the ART
clinic [14]. Notwithstanding these measures, disease progression in
infants, especially those infected in utero, is extremely rapid 225%
of 560 HIV-infected infants identified at ,12 weeks old as
potential participants in the CHER study were ineligible as they
already had CD4%,25, symptomatic disease or had died before
screening/enrolment [18]. Currently infant diagnostic testing is
recommended at 6 weeks of age, with ART initiation in infected
infants at 10–14 weeks of age. However, in a study to determine
optimal timing of infant diagnostic testing, it was found that 45%
of in utero-infected and 22% of intrapartum-infected infants had died
or were lost to follow-up by 14 weeks of age [55,56]. The role of
earlier PCR testing in infants needs to be explored.
First-line regimen use closely followed national guidelines. PI
use was almost completely absent outside of South Africa, but this
is likely to change. The WHO 2013 Guidelines [46] now
recommend PI-based regimens for all children ,3 years old.
The P1060 trial demonstrated better survival and virological
outcomes in children ,3 years old initiating PI based compared to
NNRTI-based therapy, irrespective of prior PMTCT exposure
[57], and a resistance surveillance study in Zimbabwe found
Figure 4. Characteristics of children,1 year of age at ART start by program year. Characteristics of children,1 year of age at ART start by
program year summarized as medians for continuous variables and proportions for categorical variables. p,0.001 for changes over program year for
all variables (Cuzick’s test for trend for continuous variables and logistic regression for categorical variables).
doi:10.1371/journal.pone.0081037.g004
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substantial NNRTI resistance in children ,18 months old without
prior exposure to NVP [58]. Similarly while TDF use was very
limited, this is likely to increase among older children. The
feasibility, cost, safety and long term outcomes of these changes
will need to be examined.
To our knowledge this is the largest study of temporal trends in
child characteristics at the start of ART in sub-Saharan Africa and
the only study including a range of settings in more than one
country to date. The number of children in our study is nearly
10% of the 337,200 children estimated to be receiving ART in
eastern and southern Africa by the end of 2010 [1]. Inclusion of
data from 3 different periods of WHO guidelines enabled us to
comment on how patient characteristics at ART start have
changed as a result of WHO and national guideline changes.
Representativeness of all children initiating ART in the region
may however be limited as cohorts contributing to IeDEA-SA
must have electronic patient databases and so are likely to be
better resourced than all programs in the region. Nevertheless, the
use of routine program data from busy clinics in this analysis,
rather than dedicated research databases, enhances representa-
tiveness. There was substantial missing data on a number of
variables, but this is true of routine monitoring data from many
settings, and it is encouraging that the proportion of missing data
for most variables decreased in later years [13,34]. Notwithstand-
ing, it is a concern that WHO Stage and/or CD4 measurement
data is missing for many children as failure to routinely perform
these assessments in all HIV-infected children may result in missed
opportunities to initiate ART before the onset of advanced disease.
It is therefore important to ensure improved access to CD4 testing
and results as well as mentorship of health care workers to ensure
regular and accurate assessment for new clinical events. The
recent WHO recommendation [46] to start treatment in all
children ,5 years of age irrespective of disease severity should
reduce missed opportunities for ART initiation due to lack of
Stage or CD4 measurement in these children. Data on key
variables of interest such as PMTCT exposure and tuberculosis
infection at ART start were too sparse to include in the analysis.
In conclusion, over time increasing numbers of children are
initiating ART at younger ages and with less severe disease in
these programs. However the proportion of infants remains low
and the proportion of children across all ages initiating ART with
severe disease remains high. It is important to continue to develop
strategies for earlier diagnosis and treatment of infants as well as to
examine long term outcomes in the era of expanding coverage of
pediatric HIV and more effective PMTCT.
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